Lunit, recognized as a leading provider of artificial intelligence (AI)-enabled solutions for cancer diagnostics and therapeutics, has unveiled its strategic expansion into the European market with the announcement of two substantial commercial agreements.
The Korean startup has secured supply contracts with TeleDiag in France and the Portuguese League Against Cancer (Liga Portuguesa Contra o Cancro; LPCC), offering AI-powered radiology solutions for chest X-ray and breast cancer detection, respectively. Through the delivery of Lunit INSIGHT CXR, a CE-marked AI-powered solution capable of detecting 10 of the most common lung abnormalities, including lung cancer, Lunit and TeleDiag aim to improve the accuracy and effectiveness of lung disease detection, leveraging TeleDiag's extensive network of over 600 radiologists serving more than 300 medical practices and screening over 600,000 patients annually, signifying a significant advancement in integrating AI technology into the French healthcare system.
Concurrently, Lunit has entered into a supply agreement with the central region branch of the Portuguese League Against Cancer (LPCC) to provide its FDA-cleared and CE-marked AI-powered solution for mammography analysis, Lunit INSIGHT MMG, with plans to analyse approximately 100,000 mammograms annually over the next three years, thus further demonstrating Lunit's commitment to advancing cancer diagnostics through innovative AI technology.
Click here to read the original news story.